Shree Ganesh [SGRL] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Shree Ganesh
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Shree Ganesh wins in 7 metrics, Aarti Drugs wins in 12 metrics, with 0 ties. Aarti Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Shree Ganesh | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 31.71 | 23.77 | Aarti Drugs |
| Price-to-Book Ratio | 4.78 | 3.28 | Aarti Drugs |
| Debt-to-Equity Ratio | 26.44 | 44.92 | Shree Ganesh |
| PEG Ratio | -1.62 | -21.01 | Aarti Drugs |
| EV/EBITDA | 18.06 | 17.16 | Aarti Drugs |
| Profit Margin (TTM) | 20.16% | 7.80% | Shree Ganesh |
| Operating Margin (TTM) | 19.77% | 10.11% | Shree Ganesh |
| EBITDA Margin (TTM) | 19.77% | 10.11% | Shree Ganesh |
| Return on Equity | 15.89% | 12.28% | Shree Ganesh |
| Return on Assets (TTM) | 12.02% | 6.53% | Shree Ganesh |
| Free Cash Flow (TTM) | $74.69M | $674.20M | Aarti Drugs |
| Dividend Yield | N/A | 0.22% | N/A |
| 1-Year Return | -35.65% | -1.73% | Aarti Drugs |
| Price-to-Sales Ratio (TTM) | 6.39 | 1.85 | Aarti Drugs |
| Enterprise Value | $7.04B | $50.76B | Aarti Drugs |
| EV/Revenue Ratio | 6.49 | 2.10 | Aarti Drugs |
| Gross Profit Margin (TTM) | 76.08% | 36.77% | Shree Ganesh |
| Revenue per Share (TTM) | $84 | $265 | Aarti Drugs |
| Earnings per Share (Diluted) | $17.02 | $20.66 | Aarti Drugs |
| Beta (Stock Volatility) | 0.25 | 0.21 | Aarti Drugs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Shree Ganesh vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Shree Ganesh | -0.74% | -6.27% | -7.83% | -24.44% | -33.11% | -17.95% |
| Aarti Drugs | -2.85% | 0.47% | 3.52% | 17.71% | 21.40% | 7.96% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Shree Ganesh | -35.65% | 133.51% | 548.04% | 1,535.61% | 1,535.61% | 1,535.61% |
| Aarti Drugs | -1.73% | 18.09% | -4.28% | 213.79% | 2,742.22% | 2,387.47% |
Performance & Financial Health Analysis: Shree Ganesh vs Aarti Drugs
| Metric | SGRL | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹6.93B | ₹44.83B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 6,160 | 276,955 |
| 90 Day Avg. Volume | 8,256 | 692,287 |
| Last Close | ₹539.75 | ₹491.75 |
| 52 Week Range | ₹525.50 - ₹950.00 | ₹312.00 - ₹635.00 |
| % from 52W High | -43.18% | -22.56% |
| All-Time High | ₹950.05 (Jul 22, 2024) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -43.19% | -52.12% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.01% | 0.06% |
| Quarterly Earnings Growth | -0.26% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.20% | 0.08% |
| Operating Margin (TTM) | 0.20% | 0.10% |
| Return on Equity (TTM) | 0.16% | 0.12% |
| Debt to Equity (MRQ) | 26.44 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹113.00 | ₹149.84 |
| Cash per Share (MRQ) | ₹22.01 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹337.14M | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹230.68M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.22% |
| Last 12-Month Dividend | ₹0.00 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Shree Ganesh vs Aarti Drugs
| Metric | SGRL | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 31.71 | 23.77 |
| Forward P/E | N/A | 15.13 |
| PEG Ratio | -1.62 | -21.01 |
| Price to Sales (TTM) | 6.39 | 1.85 |
| Price to Book (MRQ) | 4.78 | 3.28 |
| Market Capitalization | ||
| Market Capitalization | ₹6.93B | ₹44.83B |
| Enterprise Value | ₹7.04B | ₹50.76B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.49 | 2.10 |
| Enterprise to EBITDA | 18.06 | 17.16 |
| Risk & Other Metrics | ||
| Beta | 0.25 | 0.21 |
| Book Value per Share (MRQ) | ₹113.00 | ₹149.84 |
Financial Statements Comparison: Shree Ganesh vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SGRL | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹244.32M | ₹6.77B |
| Cost of Goods Sold | ₹58.44M | ₹4.37B |
| Gross Profit | ₹185.88M | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹73.63M | ₹784.50M |
| EBITDA | ₹121.64M | ₹951.90M |
| Pre-Tax Income | ₹87.74M | ₹711.50M |
| Income Tax | ₹21.84M | ₹83.80M |
| Net Income (Profit) | ₹65.90M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SGRL | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹99.47M | ₹45.80M |
| Total Current Assets | ₹775.75M | ₹13.38B |
| Total Current Liabilities | ₹161.82M | ₹8.37B |
| Long-Term Debt | ₹296.08M | ₹2.86B |
| Total Shareholders Equity | ₹1.45B | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹949.68M | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SGRL | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SGRL | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 6,160 | 276,955 |
| Average Daily Volume (90 Day) | 8,256 | 692,287 |
| Shares Outstanding | 12.84M | 91.27M |
| Float Shares | 2.20M | 35.46M |
| % Held by Insiders | 0.76% | 0.61% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Shree Ganesh vs Aarti Drugs
| Metric | SGRL | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.22% |
| 3-Year Avg Annual Dividend | ₹0.33 | ₹1.00 |
| 3-Year Avg Dividend Yield | 0.15% | 0.23% |
| 3-Year Total Dividends | ₹1.00 | ₹3.00 |
| Ex-Dividend Date | Sep 07, 2023 | Feb 04, 2025 |